AMCP’s Managed Care & Specialty Pharmacy Annual Meeting to Feature New Outcomes Research from Analysis Group

April 13, 2021

Analysis Group’s Health Care practice will present 13 posters at the Academy of Managed Care Pharmacy’s (AMCP’s) Managed Care & Specialty Pharmacy Virtual Annual Meeting, which will be held April 12–16, 2021. Two of the abstracts received ribbon honors, including:

Gold ribbon

  • “Utilization and Cost of Prophylactic FVIII Treatment among Patients with Hemophilia A,” coauthored by an Analysis Group team – including Vice President Keziah Cook, Associate Kelly Adamski, and Analyst Selvam Sendhil – in collaboration with teams from BioMarin Pharmaceutical, the Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, Boston Children’s Hospital/Harvard Medical School, and Rady Children’s Hospital-San Diego.

Silver ribbon

  • “Characteristics of Real-world Users of Fluticasone Furoate/Umeclidinium/Vilanterol or Multiple-inhaler Triple Therapy in Asthma in the US,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President François Laliberté, and Manager Guillaume Germain – in collaboration with a team from GlaxoSmithKline.

 Additional poster presentations include:

  • “Cost-Effectiveness Analysis of Apomorphine Sublingual Film, Apomorphine Subcutaneous Injection, and Inhaled Levodopa Powder for the Treatment of “OFF” Episodes in Patients With Parkinson’s Disease,” coauthored by an Analysis Group team – including Managing Principal Noam Kirson, Associate Miriam Ellis and Data Scientist Ibrahima (Ibou) Dieye – in collaboration with a team from Sunovion Pharmaceuticals.
  • “Real-World Treatment Patterns, Healthcare Resource Utilization and Associated Costs among Patients with Chronic Myeloid Leukemia in Later Lines of Therapy: A SEER-Medicare Analysis,” coauthored by an Analysis Group team – including Managing Principals Eric Q. Wu and Annie Guerin, Manager Dominick Latremouille-Viau, and Associate Carmine Rossi – in collaboration with teams from Novartis Pharmaceuticals and the Medical College of Wisconsin.
  • “The Economic Impact of Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) in the United States: A Cost of Care and Budget Impact Model of Venetoclax plus Obinutuzumab Sequences for CLL Patients,” coauthored by an Analysis Group team – including Associates Nisha Hazra and Honghao Fang – in collaboration with teams from AbbVie, the Dana Farber Cancer Institute, Genentech, and the University of Washington and Fred Hutchinson Cancer Research Center.
  • “Adverse Event Costs of Darolutamide vs Apalutamide and Enzalutamide in Non-Metastatic Castration-Resistant Prostate Cancer (nmCRPC),” coauthored by an Analysis Group team – including Vice President Rajeev Ayyagari and Managers Viviana García-Horton and Emi Terasawa, in collaboration with teams from Bayer AG and GenesisCare.
  • “Real-World Adherence to Tetrabenazine or Deutetrabenazine Among Patients With Huntington’s Disease,” coauthored by an Analysis Group team – including Vice President Rajeev Ayyagari, Manager Viviana García-Horton, and Senior Analysts Karen Yang and Ahmed Noman – in collaboration with teams from Teva Pharmaceuticals and the Vanderbilt University Medical Center.
  • “Budget Impact Analysis of Tazemetostat for Third-Line or Later (3L+) Relapsed or Refractory Follicular Lymphoma,” coauthored by an Analysis Group team – including Principal Dave Nellesen, Manager David Proudman, and Associate Aparna Gomes – in collaboration with a team from Epizyme.
  • “The Economic Burden of Post-traumatic Stress Disorder in Adults in the United States from a 2018 Societal Perspective,” coauthored by an Analysis Group team – including Managing Principals Annie Guérin and Patrick Lefebvre, Vice President Martin Cloutier, and Manager Patrick Gagnon-Sanschargrin – in collaboration with teams from Otsuka Pharmaceutical Development & Commercialization, Lundbeck, and the Tuscaloosa Veterans Affairs Medical Center.
  • “Treatment Patterns among Adults with Attention-Deficit/Hyperactivity Disorder in the United States – A Retrospective Claims Analysis,” coauthored by an Analysis Group team – including Managing Principals Annie Guérin and Patrick Lefebvre, Vice President Martin Cloutier, and Manager Patrick Gagnon-Sanschargrin – in collaboration with teams from Otsuka Pharmaceutical Development & Commercialization and the Center for Psychiatry and Behavioral Medicine.
  • “Healthcare Resource Utilization and Costs Among Patients with EGFR Mutal Metastic MSCLC Who Have Discontinued EGFR-TKI and Platinum-Based Chemotherapy Regimens,” coauthored by an Analysis Group team – including Managing Principal Eric Q. Wu, Vice President Jipan Xie, Manager Raluca Ionescu-Ittu, Associate Ameur Manceur, and Analyst Selvam Sendhil – in collaboration with a team from Daiichi Sankyo.
  • “Clinical and Economic Burden Associated with New Oral Corticosteroid Users with Systemic Lupus Erythematosus in the United States,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Maral DerSarkissian, and Analyst Jensen Vu – in collaboration with a team from GlaxoSmithKline.

Read more about AMCP’s Managed Care & Specialty Pharmacy Annual Meeting 2021